Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
Catalyst Pharmaceuticals (CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has scheduled its first quarter 2025 financial results release for May 7, 2025, after market close.
The company will host a conference call and webcast the following day, May 8, 2025, at 8:30 AM ET. During this event, management will discuss financial results and provide a business update. Investors can access the webcast through the Investors section of Catalyst's website, with a replay available for at least 30 days after the event.
Catalyst Pharmaceuticals (CPRX), un'azienda biofarmaceutica in fase commerciale specializzata in malattie rare e difficili da trattare, ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per il 7 maggio 2025, dopo la chiusura del mercato.
La società terrà una conference call e una diretta web il giorno seguente, 8 maggio 2025 alle 8:30 ET. Durante l'evento, la direzione discuterà i risultati finanziari e fornirà un aggiornamento sull'attività aziendale. Gli investitori potranno accedere alla diretta attraverso la sezione Investors del sito web di Catalyst, con la possibilità di rivederla per almeno 30 giorni dopo l'evento.
Catalyst Pharmaceuticals (CPRX), una compañía biofarmacéutica en etapa comercial especializada en enfermedades raras y de difícil tratamiento, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el 7 de mayo de 2025, después del cierre del mercado.
La empresa realizará una llamada conferencia y una transmisión en línea al día siguiente, 8 de mayo de 2025 a las 8:30 AM ET. Durante este evento, la dirección discutirá los resultados financieros y ofrecerá una actualización comercial. Los inversores podrán acceder a la transmisión a través de la sección Investors del sitio web de Catalyst, con una repetición disponible por al menos 30 días después del evento.
Catalyst Pharmaceuticals (CPRX)는 희귀하고 치료가 어려운 질환을 전문으로 하는 상업 단계의 생명공학 제약회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 7일 장 마감 후로 예정했습니다.
회사는 다음 날인 2025년 5월 8일 오전 8시 30분(동부시간)에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 이 행사에서 경영진은 재무 실적을 논의하고 사업 현황을 업데이트할 것입니다. 투자자들은 Catalyst 웹사이트의 Investors 섹션을 통해 웹캐스트에 접속할 수 있으며, 행사 후 최소 30일간 다시보기 서비스를 이용할 수 있습니다.
Catalyst Pharmaceuticals (CPRX), une entreprise biopharmaceutique en phase commerciale spécialisée dans les maladies rares et difficiles à traiter, a programmé la publication de ses résultats financiers du premier trimestre 2025 pour le 7 mai 2025, après la clôture du marché.
L'entreprise organisera une conférence téléphonique et une diffusion en direct le lendemain, le 8 mai 2025 à 8h30 (heure de l'Est). Lors de cet événement, la direction discutera des résultats financiers et fournira une mise à jour sur les activités. Les investisseurs pourront accéder à la diffusion via la section Investors du site web de Catalyst, avec une rediffusion disponible pendant au moins 30 jours après l'événement.
Catalyst Pharmaceuticals (CPRX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene und schwer behandelbare Krankheiten spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für den 7. Mai 2025 nach Börsenschluss geplant.
Das Unternehmen wird am folgenden Tag, dem 8. Mai 2025 um 8:30 Uhr ET, eine Telefonkonferenz und eine Webcast veranstalten. Während dieser Veranstaltung wird das Management die Finanzergebnisse besprechen und ein Geschäftsupdate geben. Investoren können über den Investors-Bereich auf der Website von Catalyst auf den Webcast zugreifen, der mindestens 30 Tage nach der Veranstaltung als Aufzeichnung verfügbar sein wird.
- None.
- None.
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET
CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025.
Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update.
| Conference Call & Webcast Details | |
| Date: Time: US/Canada Dial-in Number: International Dial-in Number: | May 8, 2025 8:30 AM ET (833) 316-2483 (785) 838-9284 |
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on Catalyst’s website for at least 30 days following the date of the event.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 ir@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com
FAQ
When will Catalyst Pharmaceuticals (CPRX) release Q1 2025 earnings?
How can investors join Catalyst Pharmaceuticals' Q1 2025 earnings call?
Where can I find the replay of CPRX's Q1 2025 earnings webcast?
What is Catalyst Pharmaceuticals' main business focus?
